Tuesday Nov 19
Applied Clinical Trials
Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual...
OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Omeros Corporation To Present Data From OMS302 Phase 3 Clinical...
The presentation, "Two Phase 3 Trials of OMS302 in Irrigation Solution for Maintenance of Mydriasis in Intraocular Lens Replacement " includes key analyses from the Phase 3 program for OMS302.
Omeros Corp. (OMER) Releases Quarterly Earnings, Misses Expectations By $0.02 EPS
Omeros Corp. posted its quarterly earnings results on Thursday. The company reported EPS for the quarter, missing the Thomson Reuters consensus estimate of by $0.02, ARN reports.
Omeros Corporation Reports Third Quarter 2013 Financial Results
Omeros Corporation , a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2013.
Omeros reports 'positive' eye drug results
Omeros Corp. shares were up in early Tuesday trading after the Seattle company announced "positive data" from the results of a test of its eye drug.